计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
M127627-10mg |
10mg |
现货 ![]() |
| |
M127627-50mg |
50mg |
现货 ![]() |
| |
M127627-100mg |
100mg |
现货 ![]() |
| |
M127627-250mg |
250mg |
现货 ![]() |
| |
M127627-1g |
1g |
现货 ![]() |
| |
M127627-5g |
5g |
现货 ![]() |
|
英文别名 | 2-(4-(3S)-3-piperidinylphenyl)-2H-indazole-7-carboxamide | 1038915-60-4 | STL556264 | LABETALOL [WHO-DD] | DTXCID8068620 | BCP9000940 | DB11793 | MK 4827 | s2741 | AKOS016004869 | BCP0726000077 | MK-4827/MK4827 | NIRAPARIB [INN] | C19H20N4O | MK-4827(Nira |
---|---|
规格或纯度 | Moligand™, ≥98% |
英文名称 | MK-4827 (Niraparib) |
生化机理 | MK-4827 是一种强效、选择性 PARP 1/2 抑制剂,对 PARP1 和 PARP2 的 IC50 分别为 3.8 和 2.1 nM。MK-4827 具有潜在的抗肿瘤活性。在全细胞试验中,MK-4827 可阻止 PARP 的活性,其 EC50 值为 4 nM,从而增强 DNA 链断裂的积累,促进基因组的不稳定性和细胞凋亡。在同源重组(HR)修复缺陷的BRCA1/2缺失肿瘤和非BRCA相关HR缺陷的肿瘤细胞系中,MK-4827可诱导选择性合成致死,支持其在散发性肿瘤中的临床应用。MK-4827 具有良好的药代动力学特性,目前正在进行 I 期临床试验。MK-4827 治疗实体瘤的 I 期临床试验正在进行中。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 聚[ADP-核糖]聚合酶-1 抑制剂 |
产品介绍 |
MK-4827(Niraparib)是高活性PARP1/PARP2抑制剂,IC50分别为3.8 nM/2.1 nM,在BRCA-1和BRCA-2突变型肿瘤细胞中具有很好的活性,比对PARP3,V-PARP和Tank1的抑制性高330倍以上。 MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM;with great activity in cancer cells with mutant BRCA-1 and BRCA-2;>330-fold selective against PARP3,V-PARP and Tank1. |
ALogP | 2.2 |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 488200727 |
---|---|
分子类型 | 小分子 |
IUPAC Name | 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide |
INCHI | InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1 |
InChi Key | PCHKPVIQAHNQLW-CQSZACIVSA-N |
Canonical SMILES | C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N |
Isomeric SMILES | C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N |
PubChem CID | 24958200 |
分子量 | 320.39 |
溶解性 | DMSO |
---|---|
分子量 | 320.400 g/mol |
XLogP3 | 2.200 |
氢键供体数Hydrogen Bond Donor Count | 2 |
氢键受体数Hydrogen Bond Acceptor Count | 3 |
可旋转键计数Rotatable Bond Count | 3 |
精确质量Exact Mass | 320.164 Da |
单同位素质量Monoisotopic Mass | 320.164 Da |
拓扑极表面积Topological Polar Surface Area | 72.900 Ų |
重原子数Heavy Atom Count | 24 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 449.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
象形图 | GHS08, GHS07 |
---|---|
信号词 | Danger |
危险声明 |
H373: 通过长时间或反复暴露对器官造成损害 H302: 吞食有害 H340: 可能导致遗传缺陷 H361: 怀疑破坏生育力或未出生的孩子 |
预防措施声明 |
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264: 处理后要彻底洗手。 P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P281: 根据需要使用个人防护设备。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P330: 漱口 P203: 使用前,获取、阅读并遵守所有安全说明。 P301+P317: 如果被吞咽:请寻求医疗帮助。 P318: 如果暴露或担心,请就医。 P319: 如果你感到不适,请寻求医疗帮助。 |
Purity(HPLC) | 98-100(%) |
---|---|
NMR spectrum | Conforms to Structure |
LC-MS for identification | Conforms |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 25-04-07 | M127627 |
![]() |
分析证书 | 24-05-30 | M127627 |
![]() |
分析证书 | 24-05-30 | M127627 |
![]() |
分析证书 | 24-05-30 | M127627 |
![]() |
分析证书 | 24-05-30 | M127627 |
![]() |
分析证书 | 23-05-23 | M127627 |
![]() |
分析证书 | 23-05-23 | M127627 |
![]() |
分析证书 | 23-05-23 | M127627 |
![]() |
分析证书 | 23-05-23 | M127627 |
![]() |
分析证书 | 23-05-23 | M127627 |
![]() |
分析证书 | 23-05-23 | M127627 |
![]() |
分析证书 | 22-12-09 | M127627 |
![]() |
分析证书 | 22-10-15 | M127627 |
¥683.90
¥484.90
1. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.. Nature, 434 (7035): (913-7). [PMID:15829966] [10.1021/op500134e] |
2. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al.. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.. Nature, 434 (7035): (917-21). [PMID:15829967] [10.1021/op500134e] |
3. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ et al.. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.. N Engl J Med, 361 (2): (123-34). [PMID:19553641] [10.1021/op500134e] |
4. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV et al.. (2009) Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.. J Med Chem, 52 (22): (7170-85). [PMID:19873981] [10.1021/op500134e] |
5. Reinbolt RE, Hays JL. (2013) The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.. Front Oncol, 3 (13): (237). [PMID:24098868] [10.1021/op500134e] |
6. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.. Cancer Res, 72 (21): (5588-99). [PMID:23118055] [10.1021/op500134e] |